Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial

Heart and Vessels
Atsushi TanakaPioglitazone Reduce Inflammation and Restenosis with and without Drug Eluting Stent (PRIDE) Study Investigators

Abstract

Pioglitazone has superior antiatherosclerotic effects compared with other classes of antidiabetic agents, and there is substantial evidence that pioglitazone improves cardiovascular (CV) outcomes. However, there is also a potential risk of worsening heart failure (HF). Therefore, it is clinically important to determine whether pioglitazone is safe in patients with type 2 diabetes mellitus (T2DM) who require treatment for secondary prevention of CV disease, since they have an intrinsically higher risk of HF. This prospective, multicenter, open-label, randomized study investigated the effects of pioglitazone on cardiometabolic profiles and CV safety in T2DM patients undergoing elective percutaneous coronary intervention (PCI) using bare-metal stents or first-generation drug-eluting stents. A total of 94 eligible patients were randomly assigned to either a pioglitazone or conventional (control) group, and pioglitazone was started the day before PCI. Cardiometabolic profiles were evaluated before PCI and at primary follow-up coronary angiography (5-8 months). Pioglitazone treatment reduced HbA1c levels to a similar degree as conventional treatment (pioglitazone group 6.5 to 6.0%, P < 0.01; control group 6.5 to 5.9%, P < 0.001), wit...Continue Reading

References

Nov 27, 2002·Circulation·Yoshihisa OkamotoYuji Matsuzawa
Jun 21, 2005·Journal of the American College of Cardiology·Andreas PfütznerThomas Forst
Nov 25, 2005·Journal of Cardiovascular Pharmacology·Fabrice M A C MartensTon J Rabelink
Nov 15, 2006·JAMA : the Journal of the American Medical Association·Theodore MazzoneSteven M Haffner
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen
Oct 2, 2007·British Journal of Pharmacology·C E QuinnG E McVeigh
Feb 14, 2008·Journal of Atherosclerosis and Thrombosis·Masahiko IgarashiMakoto Tominaga
Apr 2, 2008·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN PERISCOPE Investigators
Feb 26, 2009·American Journal of Physiology. Endocrinology and Metabolism·Paska A PermanaPeter D Reaven
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
Mar 25, 2011·The New England Journal of Medicine·Ralph A DeFronzoUNKNOWN ACT NOW Study
Apr 26, 2011·Life Sciences·Akihiro KudohTsuyoshi Watanabe
Jan 27, 2012·International Journal of Cardiology·Aiko SakamotoNobukazu Ishizaka
Nov 24, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Aramesh SaremiPeter D Reaven
Sep 14, 2013·Cerebrovascular Diseases·Chien-Jung LuChung Y Hsu
May 24, 2014·JACC. Cardiovascular Interventions·Kyung Woo ParkHyo-Soo Kim
Mar 5, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Soon Jun HongDo-Sun Lim
Jan 30, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Takaaki KomatsuIsao Taguchi
Feb 18, 2016·The New England Journal of Medicine·Walter N KernanUNKNOWN IRIS Trial Investigators

❮ Previous
Next ❯

Citations

Oct 3, 2019·American Journal of Respiratory Cell and Molecular Biology·Georg HansmannStephen Y Chan
May 20, 2021·Cardiovascular Diabetology·Lorenzo NestiAndrea Natali
May 18, 2021·Contemporary Clinical Trials Communications·Ludmila Gouveia-EufrasioDaniel Assis Santos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.